|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, MAPK pathway activity plays a key role in EGF- and IFNγ-induced PD-L1 expression in lung adenocarcinoma without targetable genetic alterations and may present a target to improve the efficacy of immunotherapy.© 2019 The Authors.
|
30972766 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptors (EGFR) significantly prolong the survival of lung adenocarcinoma patients with sensitizing EGFR mutations.
|
30552364 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
From the results of in vitro studies of migration and invasion assays using EGFR-TKI-sensitive and -resistant cell lines and phosphorylation antibody arrays using EGF and rapamycin, we first demonstrate that overexpression of MMP-1, which might follow activation of a mammalian target of rapamycin (mTOR) pathway, plays an important role in the migration and invasion abilities of EGFR-TKI-resistant lung adenocarcinoma.
|
29463039 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Co-immunoprecipitation assay found that NEDD4 is associated with EGFR complex upon EGF stimulation, and IHC staining indicates that NEDD4 is co-expressed with EGFR in lung adenocarcinoma tumor tissues, suggesting that NEDD4 might mediate lung cancer cell migration by interaction with the EGFR signaling complex.
|
29455656 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the chemotherapeutics available, afatinib has been shown to be effective for those with <i>epidermal growth factor receptor</i> (<i>EGFR</i>) mutation-positive lung adenocarcinoma.
|
29805772 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to evaluate the role of epidermal growth factor (EGF)-like domain multiple 6 (EGFL6) and its prognostic significance in lung adenocarcinoma.
|
29934389 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the mechanism of tight junction regulation by EGF in ADC remains unclear.
|
28160565 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EINCR1 is an EGF inducible lincRNA overexpressed in lung adenocarcinomas.
|
28732076 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
|
29228636 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To understand the impact of PIK3CA mutations on clinical characteristics and treatment response to epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) of lung adenocarcinoma, we examined PIK3CA and EGFR mutations in lung adenocarcinoma patients, and analyzed their clinical outcomes.
|
27734950 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert consensus has defined minimum requirements for routine testing and identification of epidermal growth factor (EGFR) mutations (15% of tumors harbor EGFR exon 19 deletions or exon 21 L858R substitutions) and anaplastic lymphoma kinase (ALK) rearrangements (5% of tumors) in advanced lung adenocarcinomas (ACs).
|
26620497 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular testing of lung adenocarcinomas for epidermal growth factor (EGFR) mutations and an anaplastic lymphoma kinase (ALK) translocation is important to guide directed therapy with tyrosine kinase inhibitors.
|
25596245 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study.
|
26625757 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Stable knockdown (KD) of CIP4 in lung adenocarcinoma H1299 cells, expressing wild-type EGFR, led to increased EGFR levels on the cell surface and defects in sustained activation of Erk kinase in H1299 cells treated with EGF.
|
25174397 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Both malignant tumors expressed high levels of epidermal growth factor receptors (EGFR) detected by immunohistochemistry (IHC), with membranous staining on the majority of malignant cells corresponding to maximum IHC scores of 290 and 300, respectively, for the MM and the ACL.
|
24233154 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
The therapeutic choice for patients with lung adenocarcinoma depends on the presence of EGF receptor (EGFR) mutations.
|
23243218 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Kinase domain mutations of the EGF receptor (EGFR) are common oncogenic events in lung adenocarcinoma.
|
24063894 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Collectively, our in vivo and in vitro findings support that TWIST1 collaborates with the EGF pathway in promoting EMT in EGFR mutated lung adenocarcinoma and that large series of EGFR mutated lung cancer patients are needed to further define the prognostic role of TWIST1 reactivation in this subgroup.
|
22272264 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most lung adenocarcinoma-associated EGF receptor (EGFR) mutations confer sensitivity to specific EGFR tyrosine kinase inhibitors.
|
22317760 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using an adenoviral system, we expressed DN-STAT5 in human lung adenocarcinoma A549 cells in order to broaden the investigation and to determine the role of STAT5 in EGF-mediated COX-2 gene expression.
|
21617857 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since a high percentage of lung adenocarcinoma in Asian female nonsmokers contains activating hotspot mutations in epidermal growth factor receptors (EGFR), we hypothesized that NAT2 polymorphisms might represent a risk factor in lung cancer with EGFR mutations.
|
18706736 |
2009 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1.
|
19570984 |
2009 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Gefitinib treatment should be considered for patients with carcinomatous meningitis and lung adenocarcinoma harboring a mutated EGF gene.
|
18441512 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results indicate that the activation of the EGF receptor by overexpressing LN5-integrin-FAK signaling pathway may play a crucial role in BAC growth and AE metastasis in human lung adenocarcinoma.
|
15856467 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Similarly, EGF-receptor content often increases in human lung adenocarcinomas but decreases in the mouse tumors.
|
9659582 |
1998 |